Nightmare Risk Comparison of Ramelteon, Doxepin, and Suvorexant

Medication Side Effect Profiles

The American Academy of Sleep Medicine's meta-analysis documented that ramelteon has an overall favorable side effect profile with adverse events no different from placebo, including headache, nausea, upper respiratory infection, and nasopharyngitis 1, 2
The American Academy of Sleep Medicine's meta-analysis of doxepin 3-6 mg documented headache, diarrhea, somnolence, and upper respiratory symptoms as the primary adverse effects 1, 2
Tricyclic antidepressants, such as doxepin, can affect REM sleep and dream content at higher doses, but low-dose doxepin (3-6 mg) has significantly fewer side effects than antidepressant doses 1

The FDA specifically warns about daytime impairment and abnormal sleep behaviors with suvorexant, which represents a critical safety distinction 3
The American College of Physicians guideline emphasizes the need to discuss harms including next-day effects and abnormal sleep behaviors when considering suvorexant 3

For patients concerned about nightmare risk, the first choice is ramelteon 8 mg, which has a documented single case report of nightmares with complete resolution upon discontinuation, otherwise a placebo-equivalent adverse event profile 1, 2
The second choice is low-dose doxepin 3-6 mg, which has no documented nightmare risk in guideline meta-analyses, though class effects of tricyclics warrant consideration 1, 2
The third choice is suvorexant, which has a higher overall adverse event burden including abnormal sleep behaviors, making it less favorable when nightmare avoidance is priority 3